CD5 CAR T (CT125B) therapy ( Beijing Boren Hospital)

N/A

Report date: 2024/11/15 20:00:35

Base Information

Drug NameCD5 CAR T (CT125B) therapy ( Beijing Boren Hospital)
Drug Alias NameCD5 CAR T (CT125B)CD5 CAR T (CT125B)CT125BCD5 CAR T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesBeijing Gao Boren Hospital Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Gao Boren Hospital Co Ltd
Active IndicationsN/A
Inactive IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A